ClinicalTrials.gg
CompletedNCT03933293Updated Mar 2, 2023

A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH

A Phase 2 interventional study of AK102 and Statins in Homozygous Familial Hypercholesterolemia, sponsored by Akeso. Completed at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-02.

Sponsored by Akeso · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Homozygous Familial Hypercholesterolemia with a site in China — 5 open to participants now, 6 under way, 2 of them phase 3. Homozygous Familial Hypercholesterolemia · China.

Enrollment
9th of 11
10 · median 20
Started
2019
with 2 others
Phase 2
5 of 12
3 open now
Registered
2nd of 12
by date
Lead sponsor
1 of 12
Akeso

Among the 12 studies in Homozygous Familial Hypercholesterolemia with a site in China, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2019, is one of 5 in phase 2, and was the 2nd registered.

Homozygous Familial Hypercholesterolemia

68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.

Browse Homozygous Familial Hypercholesterolemia studies →

Open to participants now

5 of the 12 studies in Homozygous Familial Hypercholesterolemia with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 12 Homozygous Familial Hypercholesterolemia studies recruiting now, 6 (50%) set no upper age limit and 5 (42%) stop at 75 or younger; 8 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Homozygous Familial Hypercholesterolemia with a site in China, or all of them as a file.
02

Study summary

AK102 is being developed for the treatment of HoFH. The study will be conducted in 2 parts, part 1 is open label, single arm study to evaluate the safety, tolerability and efficacy of PCSK9 inhibitor AK102, and part 2 is double blind, randomized, placebo controlled study to evaluate the efficacy and safety of PCSK9 inhibitor AK102. The treatment period will last 12 week.

03

Conditions studied

  • Homozygous Familial Hypercholesterolemia

Keywords

  • HoFH
  • LDL-C
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females, ≥18 years of age with a diagnosis of homozygous familial hypercholesterolemia by genetic confirmation or a clinical diagnosis based on a history of an untreated low-density lipoprotein cholesterol (LDL-C) concentration >500 mg/deciliter (dL) [13 millimoles/liter (mmol/L)] together with either xanthoma before 10 years of age or evidence of heterozygous familial hypercholesterolemia in both parents
  • Stable on pre-existing, lipid-lowering therapies (statins in combination with ezetimibe) for at least 4 weeks with no planned medication or dose change for the duration of study participation
  • Fasting central lab LDL-C concentration >130 mg/dL (3.4 mmol/L) and triglyceride concentration \<400 mg/dL (4.5 mmol/L).
  • Body weight of 40 kilograms (kg) or greater at screening

Exclusion criteria

Exclusion Criteria:

  • Received LDL plasma replacement therapy within 8 weeks before product administration
  • Received Lomitapide or Mipomersen within 5 months before Investigational product administration
  • Received prior treatment with PCSK9 inhibitors or AK102.
  • Unexplained creatine kinase (CK) ≥ 5 times the (ULN)
  • Subjects with untreated chronic or chronic hepatitis B virus (HBV) DNA exceeding 500 IU/ mL or active virus (HCV) should be excluded. Subjects with non-active HBsAg carriers, treated and stable hepatitis B (HBV DNA \<500 IU/ mL) , and cured hepatitis C can be enrolled. Subjects with positive HCV antibodies are eligible only if the HCV RNA test results are negative.
  • Known allergic reactions to any ingredients of AK102
  • Any other condition(s) that would compromise the safety of the patient or compromise the quality of the clinical study as judged by the Investigator and/or Medical Monitor.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    AK102

    450mg AK102, Q4W, subcutaneous injection

    Drug: AK102 · Drug: Statins · Drug: Ezetimibe

  • Placebo comparator
    placebo

    Placebo, Q4W, subcutaneous injection

    Drug: Statins · Drug: Ezetimibe

Interventions

  • DrugAK102

    450mg, Q4W, subcutaneous injection

  • Lipid-lowering therapies

  • Lipid-lowering therapies

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12

    Time frame: Week 12

  2. Incidence of treatment-emergent adverse events as assessed by CTCAE V5.0(only for part 1)

    Time frame: From baseline through 12 weeks

Secondary outcomes

  1. Percent Change From Baseline in High-density lipoprotein (HDL) cholesterol

    Time frame: From baseline through 12 weeks

  2. Percent Change From Baseline in non High-density lipoprotein (non-HDL) cholesterol

    Time frame: From baseline through 12 weeks

  3. Percent Change From Baseline in Serum Triglyceride (TG)

    Time frame: From baseline through 12 weeks

  4. Percent Change From Baseline in Apolipoprotein B (Apo B)

    Time frame: From baseline through 12 weeks

  5. Percent Change From Baseline in Apolipoprotein A-I (Apo A-I)

    Time frame: From baseline through 12 weeks

  6. Percent Change From Baseline in Total Cholesterol(TC)

    Time frame: From baseline through 12 weeks

  7. Change From Baseline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

    Time frame: From baseline through 12 weeks

  8. Concentrations of AK102 in Serum

    Time frame: Part 1: Day 1,Day 2, Day 4, Day 8, Day 15, Day 22, D29, D57. Part 2: Day 1, Day 29, Day 57

  9. Number of subjects who develop detectable anti-drug antibodies (ADAs)

    Time frame: From baseline through 12 weeks

07

Study locations

2 sites
  • Peking Union Medical College Hospital
    Beijing, Beijing 100000, China
  • Beijing Anzhen Hospital
    Beijing, Beijing 100029, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Mar 2021, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2019
First posted
May 1, 2019
StartActual
May 13, 2019
Primary completionActual
Mar 15, 2021
CompletionActual
Mar 15, 2021
Last update
Mar 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03933293
Lead sponsor
Akeso
Collaborators
AD Pharmaceuticals Co., Ltd.
Responsible party
Sponsor
First posted
May 1, 2019
Start date
May 13, 2019
Primary completion
Mar 15, 2021
Completion
Mar 15, 2021
Last update
Mar 2, 2023

Study contacts

Shuyang Zhang, MD
principal investigator · Peking Union Medical College Hospital
Lvya Wang
principal investigator · Beijing Anzhen Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ebronucimab

Start the discussion